TrueBinding, a California startup addressing Alzheimer’s from a different angle than most other biotechs, has secured more than $50 million in additional capital. But it’s also gone through two rounds of layoffs in recent weeks, according to LinkedIn posts.
The biotech sent in paperwork on a $57.7 million raise this week, but the SEC filing outlines an originally targeted $78 million round. The company brought in 11 investors for the offering, which kicked off in March.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters